| Delaware (State or other jurisdiction of incorporation or organization) | | | 45-3757789 (I.R.S. Employer Identification Number) | |
| Large accelerated filer | | | ☐ | | | Accelerated filer | | | ☐ | |
| Non-accelerated filer | | | ☒ | | | Smaller reporting company | | | ☒ | |
| | | | | | | Emerging growth company | | | ☒ | |
| | |||||||||||||||||||||
Title of each class of securities to be registered | | | Amount to be Registered(1)(2) | | | Proposed Maximum Offering Price Per Share(1)(2) | | | Maximum Aggregate Offering Price(1)(2) | | | Amount of Registration Fee(3)(4) | | |||||||||
Common stock, $0.0001 par value per share | | | | | | | | | | | | | | | | | | | | | | |
Preferred stock, $0.0001 par value per share | | | | | | | | | | | | | | | | | | | | | | |
Warrants | | | | | | | | | | | | | | | | | | | | | | |
Total | | | | $ | 200,000,000 | | | | | | | | $ | 200,000,000 | | | | | $ | 21,570 | | |
| | | Page | | ||||
| | | | ii | | | ||
| | | | 1 | | | ||
| | | | | | |||
| | | | 6 | | | ||
| | | | | | |||
| | | | 9 | | | ||
| | | | | | |||
| | | | 15 | | | ||
| | | | | | |||
| | | | | | |||
| | | | 17 | | | ||
| | | | 18 | | |
| | | Beneficial Ownership Prior to this Offering | | | Maximum Number of Shares to be Sold Pursuant to this Prospectus(2) | | | Beneficial Ownership After this Offering(1) | | |||||||||||||||||||||
Name of Selling Stockholder | | | Number of Shares | | | Percentage of Outstanding Common Stock | | | Number of Shares | | | Percentage of Outstanding Common Stock | | ||||||||||||||||||
Eventide Healthcare Innovation Fund I LP(3) | | | | | 1,394,336 | | | | | | 9.99% | | | | | | 6,681,749 | | | | | | — | | | | | | — | | |
Cormorant Global Healthcare Master Fund, LP(4) | | | | | 1,394,336 | | | | | | 9.99% | | | | | | 4,454,479 | | | | | | — | | | | | | — | | |
AI Biotechnology LLC(5) | | | | | 1,394,336 | | | | | | 9.99% | | | | | | 8,909,033 | | | | | | — | | | | | | — | | |
Citadel CEMF Investments Ltd.(6) | | | | | 1,181,088 | | | | | | 8.46% | | | | | | 1,181,088 | | | | | | — | | | | | | — | | |
Soleus Capital Master Fund, L.P.(7) | | | | | 890,868 | | | | | | 6.38% | | | | | | 890,868 | | | | | | — | | | | | | — | | |
Entities affiliated with Baker Bros. Advisors LP(8) | | | | | 696,470 | | | | | | 4.99% | | | | | | 6,681,813 | | | | | | — | | | | | | — | | |
Entities affiliated with Acorn Bioventures(9) | | | | | 696,470 | | | | | | 4.99% | | | | | | 3,118,147 | | | | | | — | | | | | | — | | |
Delaware Street Capital Master Fund, L.P.(10) | | | | | 696,470 | | | | | | 4.99% | | | | | | 2,227,244 | | | | | | 115,000 | | | | | | * | | |
Entities affiliated with Parkman(11) | | | | | 696,470 | | | | | | 4.99% | | | | | | 1,781,785 | | | | | | — | | | | | | — | | |
Entities affiliated with LifeSci Ventures(12) | | | | | 696,467 | | | | | | 4.99% | | | | | | 1,336,321 | | | | | | — | | | | | | — | | |
AlphaCentric LifeSci Healthcare Fund(13) | | | | | 668,151 | | | | | | 4.79% | | | | | | 668,151 | | | | | | — | | | | | | — | | |
Lytton-Kambara Foundation(14) | | | | | 455,374 | | | | | | 3.26% | | | | | | 445,434 | | | | | | 9,940 | | | | | | * | | |
Micro Cap Partners, L.P.(15) | | | | | 445,434 | | | | | | 3.19% | | | | | | 445,434 | | | | | | — | | | | | | — | | |
Worldwide Healthcare Partners LLC(16) | | | | | 445,434 | | | | | | 3.19% | | | | | | 445,434 | | | | | | — | | | | | | — | | |
| | | Amount | | |||
SEC registration fee | | | | $ | 21,570 | | |
Printing and engraving | | | | | * | | |
Accounting services | | | | | * | | |
Legal fees of registrant’s counsel | | | | | * | | |
FINRA filing fee | | | | | * | | |
Transfer agent and trustee fees | | | | | * | | |
Miscellaneous | | | | | * | | |
Total | | | | | * | | |
| | | Amount | | |||
SEC registration fees | | | | $ | 18,547 | | |
Accounting fees and expenses | | | | | 40,000 | | |
Legal fees and expenses | | | | | 250,000 | | |
Miscellaneous fees and expenses | | | | | 6,453 | | |
Total | | | | $ | 315,000 | | |
| | | | | | Incorporated by Reference | | | | | ||||||
Exhibit No. | | | Description | | | Form | | | Date | | | Number | | | Filed Herewith | |
1.1* | | | Form of Underwriting Agreement. | | | | | | | | | | | | | |
4.1 | | | | | S-1/A | | | January 12, 2018 | | | 4.2 | | | | | |
4.2* | | | Form of Preferred Stock Certificate. | | | | | | | | | | | | | |
4.3* | | | Form of Warrant Certificate. | | | | | | | | | | | | | |
5.1 | | | | | | | | | | | | | | X | | |
23.1 | | | | | | | | | | | | | | X | | |
23.2 | | | Consent of Kesselman & Kesselman, independent registered public accounting firm of VYNE Therapeutics Inc. | | | | | | | | | | | | X | |
23.3 | | | Consent of Skadden, Arps, Slate, Meagher & Flom LLP (included in Exhibit 5.1). | | | | | | | | | | | | X | |
24.1 | | | | | | | | | | | | | | X | |
| | | | | | | Incorporated by Reference | | |||||||||
| Exhibit Number | | | Description | | | Form | | | File Number | | | Exhibit | | | Filing Date | |
| 4.1 | | | | | 10-K | | | 001-38356 | | | 3.1 | | | March 17, 2022 | | |
| 4.2 | | | | | 10-Q | | | 001-38356 | | | 3.1(b) | | | November 14, 2022 | | |
| 4.3 | | | | | 8-K | | | 001-38356 | | | 3.1 | | | January 17, 2023 | | |
| 4.4 | | | | | 8-K | | | 001-38356 | | | 3.1 | | | February 10, 2023 | | |
| 4.5 | | | | | 10-Q | | | 001-38356 | | | 3.2 | | | November 14, 2022 | | |
| 4.6 | | | | | 8-K | | | 001-38356 | | | 4.1 | | | October 30, 2023 | | |
| 5.1* | | | | | | | | | | | | | | | | |
| 10.1 | | | | | 8-K | | | 001-38356 | | | 10.1 | | | October 30, 2023 | | |
| 10.2 | | | | | 8-K | | | 001-38356 | | | 10.2 | | | October 30, 2023 | | |
| 23.1* | | | | | | | | | | | | | | | | |
| 23.2* | | | | | | | | | | | | | | | | |
| 23.3* | | | Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm | | | | | | | | | | | | | |
| 24.1* | | | | | | | | | | | | | | | | |
| 107* | | | | | | | | | | | | | | | |
| | | | VYNE THERAPEUTICS INC. | | |||
| | | | By: /s/ David Domzalski David Domzalski Chief Executive Officer | | |
| | | | | Date | | ||
| /s/ David Domzalski David Domzalski | | | Director and Chief Executive Officer | | | | |
| /s/ | | | Chief Financial Officer (Principal Financial Officerand | | | | |
| /s/ Sharon Barbari Sharon Barbari | | | Director | | | November 13, 2023 | |
| /s/ Steven Basta Steven Basta | | | Director | | | ||
| ||||||||
| /s/ Anthony Bruno Anthony Bruno | | | Director | | | | |
| /s/ Patrick LePore Patrick LePore | | | Director | | | | |
| /s/ Elisabeth Sandoval Little Elisabeth Sandoval Little | | | Director | | | |